• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Anticancer chemosensitivity profiles of human breast cancer cells assessed by in vitro DNA synthesis inhibition assay.
【24h】

Anticancer chemosensitivity profiles of human breast cancer cells assessed by in vitro DNA synthesis inhibition assay.

机译：通过体外DNA合成抑制试验评估人乳腺癌细胞的抗癌化学敏感性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The present study was designed to assess the profile of the chemosensitivity of breast cancer cells and to screen effective agents for combination regimens. Chemosensitivity to anticancer agents was assessed by the 3H-thymidine incorporation assay, as the rate of inhibition of DNA synthesis in 145 samples (88 primary and 57 metastatic or recurrent lesions) from 136 patients with breast cancer. The correlations of the anticancer agents with various clinicopathological factors were analysed. The effectiveness of the agents was classified as a rate of inhibition on log scale as follows: highly sensitive (> or = 30%), moderately sensitive (25-30%), slightly sensitive (20-25%), resistant (< 20%). The chemosensitivity of breast cancer showed variations according to tumor location: primary lesions seemed to be slightly sensitive to carboquone (CQ), adriamycin (ADR), and cytosine arabinoside (Ara-C); nodal involvement was moderately sensitive to CQ and slightly sensitive to Ara-C, 5-FU, ADR, mitomycin-C (MMC), and cisplatin (CDDP); malignant effusions were highly sensitive to ADR, moderately sensitive to CQ, and slightly sensitive to Ara-C and CDDP; local recurrences were slightly sensitive to Ara-C, CQ and 5-FU; vincristine (VCR) and nimustine chloride (ACNU), however, seemed to be ineffective against breast cancer. There were significant correlations in chemosensitivity between most agents, but no correlation was found between 5-FU and CDDP, 5-FU and ACNU, MMC and VCR, ADR and CDDP, ADR and VCR, and ADR and ACNU. There were no differences in chemosensitivity between stages of primary lesions or between estrogen receptor-positive and -negative tumors. In 10 patients, simultaneous nodal involvement was more sensitive to the agents than were primary lesions, and the correlation of chemosensitivity to ADR and CQ between such lesions was significant. On the other hand, there was no significant difference or correlation of chemosensitivity between the original lesions and recurrent ones after chemotherapy. The heterogeneity and homogeneity in the chemosensitivity of breast cancer suggested not only the necessity of patient-specific chemotherapy based on a sensitivity assay, but also the usefulness of choosing agents for widely-applicable combination regimens against breast cancer.
机译：本研究旨在评估乳腺癌细胞化学敏感性的概况，并筛选有效的联合疗法药物。通过3H-胸苷掺入试验评估对抗癌药的化学敏感性，作为136例乳腺癌患者的145个样品（88个原发性和57个转移性或复发性病变）中DNA合成的抑制率。分析了抗癌药与各种临床病理因素的相关性。药剂的有效性按对数标度的抑制率分类如下：高度敏感（>或= 30％），中等敏感（25-30％），轻微敏感（20-25％），耐药（<20 ％）。乳腺癌的化学敏感性根据肿瘤部位的不同而有所不同：原发灶似乎对卡波醌（CQ），阿霉素（ADR）和阿糖胞苷（Ara-C）敏感;淋巴结受累对CQ中等敏感，对Ara-C，5-FU，ADR，丝裂霉素C（MMC）和顺铂（CDDP）敏感;恶性积液对ADR高度敏感，对CQ敏感，对Ara-C和CDDP敏感。局部复发对Ara-C，CQ和5-FU敏感。长春新碱（VCR）和氯化尼莫司汀（ACNU）似乎对乳腺癌无效。大多数药物之间的化学敏感性之间存在显着相关性，但在5-FU和CDDP，5-FU和ACNU，MMC和VCR，ADR和CDDP，ADR和VCR以及ADR和ACNU之间未发现相关性。在原发性病变的阶段之间或雌激素受体阳性和阴性肿瘤之间的化学敏感性没有差异。在10例患者中，同时淋巴结受累比原发灶对病原体更敏感，并且这些病灶之间对ADR和CQ的化学敏感性之间的相关性显着。另一方面，原始病变与化疗后复发的病变之间的化学敏感性之间没有显着差异或相关性。乳腺癌化学敏感性中的异质性和均质性不仅表明需要基于敏感性测定的患者特异性化学疗法，而且还表明了针对广泛适用于乳腺癌的联合治疗方案选择药物的有用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号